2min chapter

Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

CHAPTER

Septobiprols - What's Next?

The numbers on patients with elevated vancoma mysees, I thought were very intriguing. And I think currently that's probably a place we're all looking to septariline more than dapto in those kinds of patients already. So, all in all, very exciting data and kudos to the authors. Rachel, do you want to guide us through the next exciting late breaking trial? This next study is Inhale WP3.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode